Cholangiocarcinoma represents a diverse group of epithelial cancers united by late
diagnosis and poor outcomes. Specific diagnostic and therapeutic approaches are …

Cholangiocarcinoma (CCA) is an epithelial can-cer originating from the bile ducts with
features of cholangiocyte differentiation. 1 CCA is the second most common primary hepatic …

Cholangiocarcinoma (CCA) comprises a heterogeneous group of cancers with pathologic
features of biliary tract differentiation, and is presumed to arise from the intra-or extrahepatic …

BACKGROUND & AIMS: Cholangiocarcinoma, the second most common liver cancer, can
be classified as intrahepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma …

BACKGROUND & AIMS: Cholangiocarcinoma is a heterogeneous disease with a poor
outcome that accounts for 5%− 10% of primary liver cancers. We characterized its genomic …

Advanced cholangiocarcinoma continues to harbor a difficult prognosis and therapeutic
options have been limited. During the course of a clinical trial of whole genomic sequencing …

Background & Aims: Biliary tract cancer (BTC) is a highly malignant tumor, and identification
of effective therapeutic targets to improve prognosis is urgently required. Oncogenic …

Although the inflammation‐associated cytokine interleukin‐6 (IL‐6) has been implicated in
cholangiocarcinoma growth, the relationship between IL‐6 and oncogenic changes is …

Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with very poor
prognosis. Genome-wide, high-throughput technologies have made major advances in …

Cholangiocarcinoma (CCA) is the primary cancer of the bile ducts. Although it comprises
only 10%–15% of hepatobiliary neoplasms, its incidence is increasing. 1, 2 CCA arises from …